Skip to main content

Advertisement

Table 2 Randomized studies of thromboprophylaxis with LMWH compared with UFH in medical patients.

From: An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients

Study Patients LMWH UFH LMWH as effective as UFH?*
Harenberg et al. 1990 [30] Hospitalised, bedridden medical (n = 166) Dalteparin 1500 aPTT units s.c. o.d. 5000 IU s.c. t.i.d. Yes
Bergmann and Neuhart, 1996 [31] Elderly, bedridden, acutely ill medical (n = 442) Enoxaparin 20 mg s.c. o.d. 5000 IU s.c. b.i.d. Yes
Lechler et al. 1996 [32] Medical (n = 959) Enoxaparin 40 mg s.c. o.d. 5000 IU s.c. t.i.d. Yes
Harenberg et al. 1996 [33] Hospitalised, bedridden medical (n = 1968) Nadroparin 36 mg s.c. o.d. 5000 IU s.c. t.i.d. Yes
Kleber et al. 2003 [34] Severe respiratory disease or acute heart failure (n = 665) Enoxaparin 40 mg s.c. o.d. 5000 IU s.c. t.i.d. Yes
  1. *Efficacy defined as the incidence of objectively confirmed VTE in all studies.
  2. aPTT, activated partial thromboplastin time; b.i.d., twice daily; LMWH, low-molecular-weight heparin; o.d., once daily; s.c., subcutaneously; t.i.d., three times daily; UFH, unfractionated heparin; VTE, venous thromboembolism.